21 Facts About Anthony Czarnik


Anthony W Czarnik was born on 1957 and is an American chemist and inventor.


Anthony Czarnik is best known for pioneering studies in the field of fluorescent chemosensors and co-founding Illumina, Inc.


Anthony Czarnik currently serves as an adjunct visiting professor at the University of Nevada, Reno.


Anthony Czarnik worked at Ohio State University until 1993, when he was offered a position as Director of the Bio-Organic Chemistry group at Parke-Davis Research Laboratory in Ann Arbor, Michigan.


Anthony Czarnik was the founding editor of ACS Combinatorial Science, an academic journal published by the American Chemical Society.


Anthony Czarnik served as Illumina's chief scientific officer until 2000.


Anthony Czarnik was terminated from his position of CSO and later filed a wrongful termination lawsuit.


Anthony Czarnik later filed a patent law case in the United States District Court for the District of Delaware, alleging four counts against his former employer, including reputational harm for correction of named inventor under 35 USC.


In 2001, Anthony Czarnik was recruited by Sensors for Medicine and Science, Inc.


Since 2003, Anthony Czarnik has co-founded a number of biotechnology companies including Deuteria Pharmaceuticals LLC and Protia LLC.


Anthony Czarnik is a founder of RenoCares, a charity that provides support to alcohol and drug addicts convicted of misdemeanors in the form of financial aid for rehabilitation treatment, counseling, and psychological services.


Since 2016, annual Anthony Czarnik Awards are given for exceptional work in the area of chemosensors at the International Conference on Molecular Sensors and Molecular Logic Gates.


In 2007, Anthony Czarnik took part as an executive producer of Electric Heart: Don Ellis, a documentary about Don Ellis, an American jazz musician.


Anthony Czarnik became founding editor of the American Chemical Society's Journal of Combinatorial Chemistry and led research into the use of Rf ID tags for directed sorting for use in compound library synthesis.


The concept of the fluorescent chemosensors-molecular structures' ability to detect analytes was substantially developed in the book Fluorescent Chemosensors for Ion and Molecule Recognition edited by Anthony Czarnik and co-authored with other scientists.


Anthony Czarnik authored a review article in 1994, which led to more research being done worldwide, including a review of the field 23 years later.


In 2003, Anthony Czarnik gave an outline of a practical method for monitoring how chemosensors can be used to track glucose levels for diabetic patients.


Anthony Czarnik reported the first synthesis of Hexaazatriphenylene Hexanitrile, a hydrogen-free polyfunctional heterocycle with D3h symmetry, in 1986.


Anthony Czarnik's group conducted the first successful effort to discover small molecule drugs that work by binding to RNA.


In 2009, Anthony Czarnik submitted 240 patent applications covering the use of deuterium-substitution in drug discovery.


Anthony Czarnik has invented drugs such as -d1-lenalidomide and -d1-pioglitazone, for clinical studies.